Method for manufacturing biological implants and porous structures

Abstract

The present invention provides a biological implant and a method for manufacturing a porous structure, which prevents the porous structure from getting caught in a biological lumen or from fraying by providing a coating containing a polymer material on the porous structure, and also reduces the amount of coating material that can be installed. [Solution] The biological implant 100 comprises an expandable cylindrical stent 10 and a porous structure 20 arranged to cover the stent and configured to expand as the stent expands. The porous structure has a mesh-like skeletal portion 30, a plurality of void portions 40 partitioned by the skeletal portion, and a covering portion 50 made of a polymer material arranged to cover at least a part of the outer surface of the porous structure. The covering portion has uneven portions 53 formed along the surface shape of the porous structure.

Description

Technical Field

[0001] The present invention relates to a biological implant and a method for manufacturing a porous structure.

Background Art

[0002] A stent is a medical device that is delivered to a lesion in a biological lumen by a stent delivery system and then implanted to treat various diseases caused by stenosis or occlusion of the biological lumen such as blood vessels, expands the lesion such as the stenosis or occlusion part, and secures the lumen.

[0003] For example, Patent Document 1 discloses a stent provided with a cover layer composed of a knitted fabric that covers the outer periphery of an expandable stent body in order to prevent peripheral embolism (such as restenosis) during stent implantation. In the stent of Patent Document 1, when the stent body expands, the cover layer provided with meshes expands so as to follow the stent body, and it is possible to prevent the scattering of plaques and thrombi when the stent body expands.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0005] However, when a cover layer provided with meshes is arranged on the stent body, when delivering the stent to a lesion in the biological lumen, the cover layer may get caught in the biological lumen, etc., leading to fraying of the cover layer or detachment from the stent body. In relation to such problems, in the stent of Patent Document 1, a predetermined polymer material (synthetic resin) is used to fix the cover layer to the stent body, thereby preventing displacement or detachment of the cover layer.

[0006] For example, as proposed in Patent Document 1, by covering part or all of the cover layer with a polymer material, it is possible to prevent the cover layer from fraying due to the cover layer getting caught in the lumen of a biological tube, etc.

[0007] However, when polymer materials are used as components of the stent, it is desirable to reduce the amount used (the amount incorporated into the stent) as much as possible, taking into consideration the effects on the human body (e.g., inflammatory reactions caused by the polymer material).

[0008] The present invention has been made in view of the above problems, and aims to provide a biological implant and a method for manufacturing a porous structure that can prevent the porous structure from getting caught in a biological lumen or from fraying by providing a coating portion containing a polymer material on the porous structure, and can also reduce the amount of coating portion to be installed. [Means for solving the problem]

[0009] The above objectives of the present invention can be achieved by any one of the following means (1) to (10).

[0010] (1) A cylindrical stent that can be expanded in diameter, The system comprises a porous structure positioned to cover the stent and configured to expand as the diameter of the stent expands, The aforementioned porous structure is A skeletal structure arranged in a mesh-like pattern, Multiple voids partitioned by the aforementioned skeletal portion, The porous structure comprises a coating portion including a polymer material disposed to cover at least a portion of the outer surface of the porous structure, The covering portion is a biological implant having irregularities formed along the surface shape of the porous structure.

[0011] (2) The aforementioned covering portion is It has a convex portion that exhibits a convex shape at a position corresponding to the aforementioned skeletal portion, The biological implant according to (1), having a recess that exhibits a concave shape and is composed of a smaller covering amount than the convex portion at a position corresponding to the void portion.

[0012] (3) The covering portion is located at least one of the two ends of the porous structure that are positioned in the axial direction. The amount of coverage of the covering portion gradually decreases from the ends located in the axial direction of the porous structure to the central part, as described in (1) or (2).

[0013] (4) The porous structure is fixed to the stent via the covering portion, according to any one of (1) to (3).

[0014] (5) The stent has a drug-carrying portion containing a drug, The biological implant according to (4), wherein the covering portion and the porous structure are fixed via the covering portion to an area where the drug-carrying portion is not located.

[0015] (6) The biological implant according to (5), wherein the porous structure is fixed to the curved portion of the stent via the covering portion.

[0016] (7) The aforementioned polymer material is a biodegradable polymer, according to any one of (1) to (6).

[0017] (8) The polymer material has a physical property of having a Young's modulus less than 10 MPa, as described in any one of (1) to (7).

[0018] (9) A porous structure is prepared for use in a biological implant, comprising an expandable cylindrical stent and a porous structure positioned to cover the stent and configured to expand in accordance with the expansion of the stent's diameter. A method for manufacturing a porous structure, comprising dropping a coating material containing a polymer material from a nozzle onto an arbitrary portion of the outer surface of the porous structure to form a coating portion having uneven portions formed along the surface shape of the porous structure on at least a part of the porous structure.

[0019] (10) The method for manufacturing a porous structure according to (9), wherein a plurality of porous structures are obtained by cutting the porous structure at the position where the coating portion is formed.

Effects of the Invention

[0020] According to the present invention, it is possible to provide a biological implant and a method for manufacturing a porous structure that can prevent the porous structure from being caught in a biological lumen or fraying, and can reduce the amount of the coating portion loaded by providing a coating portion containing a polymer material on the porous structure.

Brief Description of the Drawings

[0021] [Figure 1] It is a schematic plan view showing a stent delivery system including a biological implant according to an embodiment. [Figure 2] It is a plan view showing a reduced-diameter state of a biological implant according to an embodiment. [Figure 3] It is an enlarged view showing a part of an expanded-diameter state of a biological implant according to an embodiment. [Figure 4] It is a perspective view showing a part of a biological implant according to an embodiment in an enlarged manner. [Figure 5] It is an axially orthogonal cross-sectional view showing a part of a biological implant according to an embodiment in an enlarged manner. [Figure 6] It is a cross-sectional view along the axial direction showing a part of a biological implant according to an embodiment in an enlarged manner. [Figure 7] It is a schematic cross-sectional view showing a part of a biological implant according to an embodiment. [Figure 8] It is a schematic cross-sectional view showing a part of a biological implant according to an embodiment. [Figure 9]This is a diagram illustrating a method for manufacturing a biological implant according to an embodiment. [Figure 10] This is a diagram illustrating a method for manufacturing a biological implant according to an embodiment. [Figure 11] This is a perspective view showing a magnified portion of the porous structure related to the modified example. [Figure 12] This is an enlarged, orthogonal cross-sectional view showing a portion of a biological implant related to a modified example. [Figure 13] This is a cross-sectional view along the axial direction, showing an enlarged portion of a biological implant related to a modified example. [Figure 14] This is a diagram illustrating a method for manufacturing a biological implant related to a modified example. [Figure 15] This is a diagram illustrating a method for manufacturing a biological implant related to a modified example. [Figure 16] This is a diagram of a porous structure that simply shows an example of the arrangement of the covering portion. [Figure 17] This is a diagram of a porous structure that simply shows an example of the arrangement of the covering portion. [Figure 18] This is a diagram of a porous structure that simply shows an example of the arrangement of the covering portion. [Figure 19] This is a diagram of a porous structure that simply shows an example of the arrangement of the covering portion. [Modes for carrying out the invention]

[0022] Embodiments of the present invention will be described below with reference to the attached drawings. Note that the following description does not limit the technical scope or meaning of terms as defined in the claims. Furthermore, the dimensional ratios in the drawings are exaggerated for illustrative purposes and may differ from actual ratios.

[0023] (Embodiment) The embodiments will be described with reference to Figures 1 to 10.

[0024] Figure 1 shows a stent delivery system 300 equipped with a biological implant 100 according to an embodiment. Figures 2 to 8 are diagrams illustrating the biological implant 100, stent 10, and porous structure 20 according to an embodiment. Specifically, Figure 2 is a schematic plan view showing the reduced diameter state of the stent 10 and porous structure 20 according to an embodiment, and Figure 3 is a schematic plan view showing the expanded diameter state of the stent 10 according to an embodiment. Figures 4 to 8 are diagrams illustrating characteristic parts of the biological implant 100 according to an embodiment. Figures 9 and 10 are diagrams illustrating the manufacturing method of the porous structure 20 according to an embodiment.

[0025] For the sake of clarity, the following directions are defined in this specification.

[0026] The longitudinal direction in which the stent 10 and the porous structure 20 extend is defined as the "axial direction." The axial direction is the direction from the tip 10A to the base 10B (or from the base 10B to the tip 10A) as shown in Figure 2, and is indicated by arrows X1-X2 in each figure.

[0027] In the stent 10 and the porous structure 20, the side inserted into the living body is referred to as the "proximal side," and the side opposite the proximal side, where the surgeon operates the stent delivery system 300, is referred to as the "proximal side." The "proximal portion" refers to the part that includes a certain range extending from the proximal (frontmost) end towards the proximal end, and the "proximal end" refers to the part that includes a certain range extending from the proximal (very proximal) end towards the proximal end. Furthermore, the rotational direction relative to the axial direction is defined as the circumferential direction and is indicated by arrows R1-R2 in the figure.

[0028] <Stent Delivery System 300> As shown in Figure 1, the biological implant 100 according to this embodiment is positioned on the outer circumference of the expandable and deflated balloon 220 provided by the balloon catheter 200.

[0029] The balloon catheter 200 comprises a long catheter body 210, a balloon 220 provided at the tip of the catheter body 210, and a hub 230 fixed to the proximal end of the catheter body 210.

[0030] The balloon catheter 200 to which the implanted biological device 100 is attached constitutes the stent delivery system 300. The stent delivery system 300 delivers the implanted biological device 100, to which the porous structure 20 is attached, in a deflated state to the lesion site, and by expanding the stent 10 and the porous structure 20 as the balloon 220 expands, the stent 10 and the porous structure 20 can be placed in the lesion site.

[0031] The balloon catheter 200 can be constructed, for example, as a rapid exchange type balloon catheter that allows the guidewire W to be introduced from near the tip of the catheter body 210 and inserted through to the tip of the balloon 220. The balloon 220 can also be constructed as a so-called over-the-wire type balloon catheter.

[0032] For example, organic polymer materials can be used as the material constituting the balloon 220. Specifically, polymer materials such as polyolefins (e.g., polyethylene, polypropylene, polybutene, ethylene-propylene copolymer, ethylene-vinyl acetate copolymer, ionomer, or mixtures of two or more of these), polyvinyl chloride, polyamide, polyamide elastomer, polyurethane, polyurethane elastomer, polyimide, fluororesin, or mixtures thereof, or elastic resin materials such as two or more of the above polymer materials can be used, and among these, polyamide resins can be preferably used as the main material.

[0033] <100 living organisms> The biological implant 100 according to this embodiment is used to treat narrowing or obstruction in blood vessels, bile ducts, trachea, esophagus, urethra, or other biological tubular lumen. The stent 10 used in the biological implant 100 is configured as a so-called balloon-expandable medical device, which is placed in a crimped state on a folded balloon 220, delivered to the lesion, and then expanded and placed in the lesion.

[0034] Furthermore, stent 10 can also be constructed as a so-called self-expanding medical device, made of a self-expanding material.

[0035] As shown in Figures 2 and 3, the biological implantation 100 comprises an expandable stent 10 and a porous structure 20 positioned to cover the stent 10 and configured to expand in accordance with the expansion of the stent 10.

[0036] <Stent 10> As shown in Figures 2 and 3, the stent 10 has a cylindrical shape that extends in the axial direction.

[0037] As shown in Figure 3, the stent 10 has linear rings 11 that form the outer circumference of a cylindrical shape with gaps, and link portions 12 that connect the rings 11 in gaps partitioned between adjacent linear rings 11 in the axial direction.

[0038] The ring 11 extends circumferentially around the stent 10 in a wave-like pattern that reciprocates in the axial direction.

[0039] The ring 11 has multiple first strut portions 14, which are made up of straight or curved lines, second strut portions 15, which are made up of straight or curved lines, and curved portions 17 formed between the first strut portions 14 and the second strut portions 15.

[0040] Furthermore, as shown in Figure 3, the ring 11 has a plurality of third strut portions 16, which are straight or curved, and are adjacent to one side of the link portion 12 in the axial direction and are provided in pairs in the circumferential direction.

[0041] The rings 11 are arranged sequentially along the axial direction. Adjacent rings 11 in the axial direction are connected and integrated by link portions 12.

[0042] The stent 10 can be, for example, a drug-eluting stent in which at least a portion of the stent 10 is coated with a drug. The drug coated on the stent 10 can be, for example, supported by a predetermined polymer to form the drug-carrying portion 60. As the polymer, for example, a biodegradable polymer can be used.

[0043] Figure 7 shows a schematic cross-sectional view of the link section 12 (or curved section 17). Figure 8 shows a schematic cross-sectional view of the first strut section 14 (or third strut section 16).

[0044] As shown in Figure 8, the drug-carrying portion 60 can be arranged, for example, on the outer surface of the first strut portion 14 and / or the outer surface 19 of the third strut portion 16 of the ring 11. On the other hand, as shown in Figure 7, it is preferable not to form the drug-carrying portion 60 on the curved portion 17 and the link portion 12 of the ring 11 (the parts where stress concentration and / or strain occur as the stent 10 expands). By configuring it in this way, when the stent 10 expands, stress will concentrate on the drug-carrying portion 60, and as a result, bending and strain will occur in the drug-carrying portion 60, which can prevent the drug-carrying portion 60 from peeling off or falling off the stent 10.

[0045] The outer surface 19 of the stent 10 (or strut) refers to the surface of the stent 10 on which the porous structure 20 is placed.

[0046] <Porous structure 20> As shown in Figures 2 and 3, the porous structure 20 has a mesh-like skeletal structure 30, a plurality of voids 40 partitioned by the skeletal structure 30, and a covering portion 50 containing a polymer material that is arranged to cover at least a portion of the outer surface of the porous structure 20.

[0047] As shown in Figure 2, the porous structure 20 is positioned to cover the outer circumference of the stent 10 and has a cylindrical shape similar to the stent 10.

[0048] The porous structure 20 has a tip portion 20A that is positioned to cover the vicinity of the tip portion 10A of the stent 10, and a base portion 20B that is positioned to cover the vicinity of the base portion 10B of the stent 10.

[0049] Preferably, the size of each of the multiple voids 40 in the porous structure 20 is smaller in area than the gap between the rings 11 of the stent 10. By adopting such a configuration, the porous structure 20 can prevent the scattering of plaque and thrombi during the expansion of the stent 10. On the other hand, preferably, the size of the voids 40 is larger than the area of ​​a single blood cell contained in the blood. This allows blood cells to pass through the voids 40. Furthermore, this allows the voids 40 to impart expandability to the porous structure 20. Therefore, when the stent 10 expands, the porous structure 20 also expands circumferentially along with the expansion of the stent 10, exhibiting good followability (expandability) to the expansion of the stent 10.

[0050] There are no particular restrictions on the patterns (shapes in the unfolded view) of the skeletal portion 30 and void portion 40 of the porous structure 20.

[0051] The porous structure 20 can be made of, for example, knitted fabric, woven fabric (braid), or molded material (a membrane-like member with cuts formed on it). If the porous structure 20 is knitted fabric, it can be made by knitting. By making the porous structure 20 by knitting, it is possible to suppress the shortening of the axial length of the porous structure 20 as the stent 10 expands. If the porous structure 20 is woven fabric, the fabric can be made using known weaving methods. Alternatively, the porous structure 20 may be made of a molded material in which holes are made in a tubular object formed by injection molding or the like. The size, shape, and number of stitches and weaves of the porous structure 20 are not particularly limited as long as they can prevent peripheral embolism when the stent 10 expands.

[0052] Figure 4 is a perspective view showing an enlarged view of the area near the base end 20B of the porous structure 20, and Figure 5 is a view showing an enlarged view of a part of the cross-section perpendicular to the axis of the base end 20B of the porous structure 20.

[0053] As shown in Figures 4 and 5, the covering portion 50 has uneven surfaces 53 formed along the surface shape of the porous structure 20.

[0054] The biological implant 100 is protected by a covering portion 50 which covers at least a portion of the porous structure 20, thereby preventing the porous structure 20 (especially the void portion 40) from getting caught on the biological lumen (e.g., blood vessel) when the biological implant 100 moves within the biological lumen. Furthermore, because the covering portion 50 of the biological implant 100 contains a polymer material, it is possible to prevent an excessive reduction in the flexibility of the area of ​​the porous structure 20 where the covering portion 50 is provided. Therefore, it is possible to prevent a decrease in the deliverability of the biological implant 100 or a decrease in the expandability of the porous structure 20 as a result of providing the covering portion 50.

[0055] Furthermore, the biological implant 100 has a coating portion 50 with uneven surfaces 53 formed along the surface shape of the porous structure 20. In other words, the coating portion 50 is not formed with a uniform thickness across all parts of the porous structure 20, and some parts of the coating portion 50 are thinner than other parts of the coating portion 50 (for example, the protrusions 51). As a result, the amount of coating portion 50 required (the volume of polymer material contained in the coating portion 50) is reduced compared to the case where the coating portion 50 is provided with a uniform thickness across the entire porous structure 20.

[0056] As shown in Figures 4 and 5, the covering portion 50 has a convex portion 53a that exhibits a convex shape at a position corresponding to the skeletal portion 30, and a recessed portion 53b that is composed of a smaller amount of covering than the convex portion 53a at a position corresponding to the void portion 40.

[0057] In the covering portion 50, the skeletal portion 30 and the void portion 40 are arranged alternately in the circumferential direction of the porous structure 20. Therefore, as shown in Figures 4 and 5, the covering portion 50 has convex portions 53a provided in the areas where the skeletal portion 30 is located and concave portions 53b provided in the areas where the void portion 40 is located, which are arranged alternately along the circumferential direction of the porous structure 20.

[0058] The porous structure 20 has a recess 53b with a small thickness formed in a part of the covering portion 50, thus reducing the amount of covering portion 50 that needs to be installed. Furthermore, because the porous structure 20 has a recess 53b formed in the covering portion 50, when the porous structure 20 expands in conjunction with the expansion of the stent 10, the expansion of the porous structure 20 at the location where the recess 53b is formed can be prevented. Therefore, by providing the recess 53b, the porous structure 20 can prevent the smooth expansion of the porous structure 20 from being hindered by the presence of the covering portion 50.

[0059] In particular, in this embodiment, as shown in Figures 4 and 5, the covering portion 50 has convex portions 53a and concave portions 53b arranged alternately in the circumferential direction. Therefore, when the porous structure 20 expands, each of the concave portions 53b located between adjacent convex portions 53a in the circumferential direction begins to expand quickly. Thus, when the porous structure 20 expands, it becomes possible to uniformly expand each part of the porous structure 20 in the circumferential direction.

[0060] As shown in Figures 2, 3, and 6, the covering portion 50 can be positioned at least one of the two ends 20A and 20B located in the axial direction (longitudinal direction) of the porous structure 20.

[0061] In this embodiment, the covering portion 50 is placed at both ends 20A and 20B of the porous structure 20. However, for example, the covering portion 50 may be placed only at the tip end 20A of the porous structure 20, or only at the base end 20B of the porous structure 20. Furthermore, it is also possible to configure the porous structure 20 so that the covering portion 50 is not provided in a certain range from each end 20A and 20B to the central part 20C (near the axial center of the porous structure 20). The following description will focus on the covering portion 50 placed at the base end 20B of the porous structure 20, but the covering portion 50 provided at the tip end 20A can be configured in the same way as the covering portion 50 placed at the base end 20B.

[0062] As shown in Figure 6, the amount of coverage of the covering portion 50 gradually decreases from the base end portion 20B located in the axial direction of the porous structure 20 to the central portion 20C. In other words, the covering portion 50 provided at the base end portion 20B of the porous structure 20 gradually decreases in thickness toward the tip end portion 20A located on the opposite side in the axial direction. Similarly, the covering portion 50 provided at the tip end portion 20A of the porous structure 20 gradually decreases in thickness toward the base end portion 20B located on the opposite side in the axial direction.

[0063] For example, as will be described later, one manufacturing method for the porous structure 20 involves preparing a porous structure longer than the length intended for use in the product and cutting it at a predetermined position. When such a manufacturing method is adopted, both ends 20A and 20B of the porous structure 20 are made up of the cut ends. Since the porous structure 20 has a mesh structure consisting of a skeletal part 30 and a void part 40, fraying and irregularities are likely to occur at the cut ends, which can result in a shape that spreads radially outward. When both ends 20A and 20B of the porous structure 20 are formed in this way, the porous structure 20 is more likely to get caught in biological tubular lumens, etc.

[0064] In this embodiment, by placing covering portions 50 on both ends 20A and 20B of the porous structure 20, it is possible to prevent the fraying and variations described above from occurring at both ends 20A and 20B. Furthermore, since the amount of covering portions 50 is gradually reduced from each end 20A and 20B located in the axial direction of the porous structure 20 toward the central part 20C, the amount of covering portions 50 can be reduced even more effectively. In addition, when moving the biological implant 100 within a biological lumen, both ends 20A and 20B in the axial direction of the porous structure 20 are prone to contact with the inner wall of the biological lumen, and are particularly likely to get caught on the porous structure 20. By covering at least one end of both ends 20A and 20B in the axial direction of the porous structure 20 with the covering portion 50, as in this embodiment, it is possible to effectively prevent the porous structure 20 from getting caught on the inner wall of the biological lumen, etc.

[0065] As shown in Figure 7, the porous structure 20 can be fixed to the stent 10 via the covering portion 50. By fixing the porous structure 20 to the stent 10 via the covering portion 50, it is possible to prevent fraying or inconsistencies in the porous structure 20 at the cutting position when the porous structure 20 is cut at the position where the covering portion 50 is provided (the application position of the covering material 50a) during the manufacturing of the porous structure 20 (see Figure 10).

[0066] The porous structure 20 can be fixed to the area of ​​the stent 10 where the drug-carrying portion 60 is not located, via the covering portion 50. By fixing the porous structure 20 to the stent 10 only in the area where the drug-carrying portion 60 is not located, the polymer material contained in the covering portion 50 can be used to properly fix the covering portion 50, the porous structure 20, and the stent 10 to each other.

[0067] Examples of areas where the drug-carrying portion 60 is not located include the curved portion 17 and / or the link portion 12. As mentioned above, stress concentration and strain are likely to occur in the curved portion 17 and / or the link portion 12 when the stent 10 is expanded, so it is not preferable to place the drug-carrying portion 60 there (see Figure 7). Therefore, it is preferable to fix the porous structure 20 to the curved portion 17 and the link portion 12, where the drug-carrying portion 60 is not provided, via the covering portion 50. In particular, since the number of curved portions 17 provided in a single stent 10 is greater than the number of link portions 12 (see Figure 3), it is more preferable to fix the porous structure 20 to at least the curved portion 17 via the covering portion 50, from the viewpoint of improving the fixing force of the porous structure 20 to the stent 10.

[0068] As described above, in this embodiment, the covering portion 50 is positioned only near both ends 20A and 20B of the porous structure 20. Therefore, for example, the porous structure 20 can be fixed to the stent 10 via the covering portion 50 at the curved portions 17 and / or link portions 12 located at both ends 20A and 20B.

[0069] The polymer material contained in the covering portion 50 is, for example, a biodegradable polymer. By constructing the covering portion 50 in this manner, the covering portion 50 can be decomposed and disappear after a predetermined period of time has elapsed since the stent 10 was implanted. Furthermore, by using a biodegradable polymer as the polymer material, the impact on the human body caused by implanting the covering portion 50 together with the stent 10 and the porous structure 20 can be reduced.

[0070] The polymer material contained in the covering portion 50 has physical properties such as a Young's modulus less than 10 MPa. By configuring the covering portion 50 in this way, it is possible to prevent the smooth expansion of the porous structure 20 from being hindered by the covering portion 50 when the stent 10 expands.

[0071] (Manufacturing method for the porous structure 20 according to the embodiment) Next, a method for manufacturing the porous structure 20 according to the embodiment will be described.

[0072] To begin manufacturing the porous structure 20, a porous structure 20 having a predetermined length in the axial direction is prepared, as shown in Figure 9.

[0073] Next, the predetermined core metal 500A is inserted through the porous structure 20.

[0074] Next, a coating material 50a containing a polymer material is applied to any portion of the outer surface of the porous structure 20, thereby forming a coating portion 50 having irregularities that conform to the surface shape of the porous structure 20 on at least a part of the porous structure 20.

[0075] The coating material 50a described above is obtained by dissolving the main material of the coating material 50a in a predetermined solvent.

[0076] The coating material 50a can be applied to the porous structure 20 using a predetermined nozzle 400A. The viscosity of the coating material 50a can be adjusted such that, for example, as it is applied to the porous structure 20 by dropping from the nozzle 400A, the coating material 50a flows along the skeletal portion 30 of the porous structure 20 and naturally penetrates into the inside of the voids 40. By adjusting the viscosity of the coating material 50a in this way, it becomes possible to form uneven portions 53 (see Figures 5 and 6) that conform to the surface shape of the porous structure 20 without applying any pressure to the porous structure 20 when dropping the coating material 50a from the nozzle 400A onto the porous structure 20.

[0077] Furthermore, when the coating material 50a, whose viscosity has been adjusted as described above, is applied to the porous structure 20, the coating material 50a flows from the application site toward both ends of the porous structure 20, and the amount of coating material 50a applied decreases as it moves axially away from the application site. Therefore, it becomes possible to form a coating portion 50 whose thickness decreases as it moves from both ends 20A and 20B toward the axial center (see Figure 6).

[0078] The viscosity of the coating material 50a can be adjusted, for example, by changing the concentration of the main material contained in the coating material 50a. The specific materials (solvent material and main material) and physical properties that make up the coating material 50a will be described later.

[0079] After applying the coating material 50a to the porous structure 20, the coating material 50a is dried. Once the coating material 50a has dried and solidified, and the coated portion 50 has been formed, multiple porous structures 20 can be obtained by cutting the porous structure 20 at the position where the coated portion 50 has been formed, as shown in Figure 10. The area near the cutting position of the porous structure 20 constitutes one of the ends 20A, 20B of the porous structure 20.

[0080] A covering portion 50 is formed at the cutting position of the porous structure 20. Therefore, the skeletal portion 30 near the cutting position of the porous structure 20 is covered on the surface by the polymer material contained in the covering portion 50. Thus, when the porous structure 20 is cut, fraying and inconsistencies in the skeletal portion 30 located at the cutting position can be prevented.

[0081] (modified version) Next, a biological implant relating to a modified embodiment described above will be explained. In the explanation of the modified embodiment, explanations that overlap with those described in the previously described embodiment will be omitted as appropriate. Unless otherwise specified, the biological implant relating to the modified embodiment can incorporate the same components as those described in the previously described embodiment.

[0082] The porous structure 20 of the biological implant 100 according to the modified example has a different configuration of the covering portion 50A compared to the covering portion 50 according to the embodiment described above.

[0083] The covering portion 50 of the porous structure 20 according to the above embodiment includes an uneven portion 53 formed along the surface shape of the porous structure 20 (see Figures 4 to 6). On the other hand, as shown in Figures 11 to 13, the covering portion 50A according to this modified example is arranged only along the skeletal portion 30 surrounding the void portion 40, and is not arranged in a position corresponding to the void portion 40.

[0084] As shown in Figures 12 and 13, the covering portion 50A is configured to form a layer that covers the outer surface of the skeletal portion 30.

[0085] In the modified porous structure 20, the covering portion 50A is not formed in a position where the void portion 40 exists. In other words, unlike the embodiment described above, there is no recess 53b in the covering portion 50 that is positioned to fill the void portion 40. Therefore, the amount of covering portion 50A to be mounted is further reduced compared to the covering portion 50 in the embodiment described above. Also, since there is no recess 53b that is positioned to fill the void portion 40 as described above, the flexibility of the porous structure 20 in a position corresponding to the void portion 40 can be improved. Furthermore, the bulkiness caused by providing the covering portion 50 when it is crimped onto the stent 10 (when it constitutes a biological implant 100) can be reduced. In addition to these, if the stent 10 is configured to include a drug-carrying portion 60, the absence of the recess 53b in the covering portion 50 that is positioned to fill the void portion 40 can improve the drug permeability of the stent 10 (the flow of drug between the outer surface 19 of the stent 10 and the inner wall of the biological lumen).

[0086] As shown in Figure 13, in the modified porous structure 20, the amount of covering portion 50A gradually decreases from the end located in the axial direction of the porous structure 20 (the base end portion 20B in the illustrated example) to the central portion (towards the direction of arrow X1 in the figure). By configuring it in this way, as explained in the above embodiment, it is possible to reduce the amount of covering portion 50A while preventing fraying and inconsistencies from occurring at the ends of the porous structure 20.

[0087] In the modified example, an example was described in which a covering portion 50A is formed on the proximal end portion 20B of the porous structure 20. However, it is also possible to adopt a configuration in which the covering portion 50A is provided on the tip portion 20A and / or the proximal end portion 20B of the porous structure 20. Furthermore, although not described here, the covering portion 50A can be configured to fix the porous structure 20 to the stent 10 at a predetermined position (for example, in an area where the drug-carrying portion 60 is not formed), similar to the embodiment described above.

[0088] (Manufacturing method for the porous structure 20 according to a modified example) Next, a method for manufacturing the porous structure 20 according to a modified example will be described.

[0089] To begin manufacturing the porous structure 20, a porous structure 20 having a predetermined length in the axial direction is prepared, as shown in Figure 14.

[0090] Next, the porous structure 20 is set in a predetermined jig 500B. The jig 500B used here can be a stepped core metal in which a small diameter section (for example, outer diameter 1.0 mm) is provided at the position where the coating material 50a is applied to the porous structure 20, and large diameter sections (for example, outer diameter 2.0 mm) are provided on both sides of the small diameter section.

[0091] Next, a coating material 50a containing a polymer material is applied to any portion of the outer surface of the porous structure 20, forming a coating portion 50A on at least a part of the porous structure 20 that is positioned only along the skeletal portion 30 surrounding the void portion 40.

[0092] The coating material 50a can be sprayed onto the porous structure 20 using a predetermined sprayer 400B. When spraying the coating material 50a onto the porous structure 20 from the sprayer 400B, the coating material 50a can be applied along the outer surface of the porous structure 20 by rotating the jig 500B. There are no particular restrictions on the specific type of sprayer 400B, but for example, a known ultrasonic sprayer can be used.

[0093] When applying the coating material with the sprayer 400B, the coating material 50a can be applied to a predetermined position on the porous structure 20 in such a way that it covers only the skeletal portion 30 (i.e., the coating material 50a does not fill the void portion 40) by adjusting the application conditions such as the viscosity of the coating material 50a, the amount sprayed (air flow rate), the application time, and the rotation speed of the jig 500B.

[0094] Furthermore, by adjusting the coating conditions as described above, the coating material 50a flows from the coating position where it is applied from the sprayer 400B toward both ends of the porous structure 20, and the amount of coating material 50a applied decreases as it moves axially away from the coating position. As a result, it becomes possible to form a coating portion 50A whose thickness decreases as it moves toward the axial center from both ends 20A and 20B (see Figure 13).

[0095] After applying the coating material 50a to the porous structure 20, the coating material 50a is dried. Once the coating material 50a has dried and solidified, and the coated portion 50A has been formed, multiple porous structures 20 can be obtained by cutting the porous structure 20 at the position where the coated portion 50A has been formed, as shown in Figure 15. The area near the cutting position of the porous structure 20 constitutes one of the ends 20A, 20B of the porous structure 20.

[0096] A covering portion 50A is formed at the cutting position of the porous structure 20. Therefore, the skeletal portion 30 near the cutting position of the porous structure 20 is covered on the surface by the polymer material contained in the covering portion 50A. Thus, when the porous structure 20 is cut, fraying and inconsistencies in the skeletal portion 30 located at the cutting position can be prevented.

[0097] (Example of arrangement of covering parts) In the embodiments and modifications described above, the tip portion 20A and / or base portion 20B were exemplified as the positions where the covering portion 50 (or covering portion 50A) is formed on the porous structure 20. However, there are no particular restrictions on the position where the covering portion 50 is provided in the biological implant according to the present invention.

[0098] For example, as shown in Figure 16, the covering portion 50 (or covering portion 50A) may be formed over the entire axial length of the porous structure 20. Alternatively, as shown in Figure 17, for example, the covering portion 50 (or covering portion 50A) may be arranged to extend linearly in the axial direction, connecting the tip portion 20A, the base portion 20B, and each end portion 20A, 20B of the porous structure 20. Alternatively, as shown in Figure 18, for example, the covering portion 50 (or covering portion 50A) may be arranged to extend spirally in the circumferential direction of the porous structure 20, connecting the tip portion 20A, the base portion 20B, and each end portion 20A, 20B of the porous structure 20. Furthermore, the covering portion 50 (or covering portion 50A) may be configured to include multiple portions arranged with gaps in the circumferential direction at each end portion 20A, 20B of the porous structure 20.

[0099] The following describes a suitable example of the materials and physical properties of each part (stent, porous structure, covering, etc.) that constitute the biological implant 100.

[0100] In a biological implant according to one embodiment, the material constituting the skeletal part of the porous structure can be a non-biodegradable material or a biodegradable resin material. However, since the biological implant is implanted in a living body, it is preferably a biodegradable resin material, more preferably a biodegradable resin material, even more preferably polyglycolic acid (PGA) or lactic acid-glycolic acid copolymer (PLGA), and particularly preferably polyglycolic acid (PGA).

[0101] The weight-average molecular weight of the resin material used in the skeletal portion of a porous structure according to one embodiment is not particularly limited, but is preferably 10,000 or more, more preferably 10,000 to 1,000,000, and even more preferably 20,000 to 500,000. Methods for measuring the weight-average molecular weight include gel permeation chromatography (GPC), light scattering, viscometric analysis, and mass spectrometry (such as TOFMASS). In this specification, the weight-average molecular weight is the value measured by GPC using polystyrene as a standard substance.

[0102] The coating portion preferably contains a polymer material, and the Young's modulus of the polymer material is greater than 0 MPa and less than 200 MPa.

[0103] (polymer material) In the present invention, the polymer material is included in the covering portion, which is arranged to cover at least a portion of the outer surface of the porous structure. Preferably, the Young's modulus of the polymer material is greater than 0 MPa and less than 200 MPa. Having the Young's modulus of the polymer material within this range makes the polymer material more deformable, which reduces the likelihood of expansion defects in the covering portion and allows the stent to be fully expanded.

[0104] The Young's modulus can be determined by cutting a test film made from the constituent material of a porous structure into the shape of a 5B dumbbell test specimen as shown in ISO 527-2:2012, and then performing a tensile test using a tensile testing machine with a constant temperature chamber (Autograph AG-1kNIS, manufactured by Shimadzu Corporation) at a 37°C atmosphere with a chuck distance of 20 mm and a test speed of 1 mm / min, and measuring the initial slope of the stress-strain curve within the elastic deformation region.

[0105] The mass ratio of the polymer material to the total mass of the coating ((mass of polymer material / total mass of the coating) × 100 (mass%)) is preferably 80% by mass or more, more preferably 90% by mass or more, even more preferably 95% by mass or more, particularly preferably 99% by mass or more, and most preferably 100% by mass.

[0106] (Young's modulus) Young's modulus (elastic modulus) is an index used to evaluate the mechanical properties of polymer materials, and it indicates the relationship between stress and strain in response to an external force applied to the material. Specifically, Young's modulus is defined as the value obtained by dividing stress by strain, and its unit is expressed in Pascals (Pa). When Young's modulus is high, the material is rigid and tends to be resistant to deformation under external force. Conversely, when Young's modulus is low, the material is flexible and easily deformed by external force.

[0107] The Young's modulus of the polymer material according to the present invention is greater than 0 MPa and less than 200 MPa, but in one embodiment, the Young's modulus may be greater than 0 MPa and 100 MPa or less, greater than 0 MPa and 50 MPa or less, greater than 0 MPa and 25 MPa or less, greater than 0 MPa and 10 MPa or less, greater than 0 MPa and 5 MPa or less, 0.1 MPa or more and 200 MPa or less, 0.1 MPa or more and 100 MPa or less, 0.1 MPa or more and 50 MPa or less, 0.1 MPa or more and 25 MPa or less, 0.1 MPa or more and 10 MPa or less, 0.1 MPa or more and 5 MPa or less, 0.5 MPa or more and 200 MPa or less The Young's modulus of the polymer material may be within the above range, which allows for more suitable flexibility of the polymer material, reduces the likelihood of expansion defects in the covering portion, and allows for more sufficient stent expansion.

[0108] (Elongation at break) The elongation at break of the polymer material according to one embodiment of the present invention may be 960% or more and 3500% or less, 960% or more and 3250% or less, 960% or more and 3000% or less, 960% or more and 2500% or less, 960% or more and 2000% or less, 1000% or more and 3500% or less, 1000% or more and 3250% or less, 1000% or more and 3000% or less, 1000% or more and 2500% or less, 1000% or more and 2000% or less, 1500% or more and 3500% or less, 1500% or more and 3250% or less, 1500% or more and 3000% or less, 1500% or more and 2500% or less, or 1500% or more and 2000% or less. Because the elongation at break of the polymer material falls within the above range, expansion defects in the coating are less likely to occur, and the ductility and deformation resistance of the polymer material are also improved, thus suppressing the rupture of the coating that occurs during stent expansion.

[0109] Here, "elongation at break" is one of the mechanical properties that indicates how much a polymer material can be stretched before it breaks, and it can be used to evaluate the ductility and deformation resistance of a polymer material. Elongation at break is usually expressed as the percentage of the final elongation relative to the initial length when a tensile force is applied to the material, and can be measured specifically by the method shown in the examples below.

[0110] (biodegradable polymer) A polymer material according to one embodiment of the present invention includes a biodegradable polymer. A biodegradable polymer is a resin that is biodegradable. Since the biological implant according to the present invention is implanted in a living body, it is preferable that the polymer material contains a biodegradable polymer so that the covering portion can be decomposed in the living body. The biodegradable polymer content in the polymer material ((mass of biodegradable polymer / total mass of polymer material) × 100 (mass%)) is preferably 80% by mass or more, more preferably 90% by mass or more, even more preferably 95% by mass or more, particularly preferably 99% by mass or more, and most preferably 100% by mass, from the viewpoint of the biodegradability of the polymer material.

[0111] The biodegradable polymer is not particularly limited, but may be at least one selected from the group consisting of, for example, polybutylene succinate (PBS), polybutylene adipate terephthalate (PBAT), polylactic acid (PLA), polyvinyl alcohol (PVA), polyglycolic acid (PGA), poly(ε-caprolactone) (PCL), polybutylene succinate-co-adipate (PBSA), polybutylene adipate terephthalate (PBAT), polyethylene terephthalate succinate (PETS), PBAT-PLA compound, starch polyester resin, cellulose acetate, cellulose, polyhydroxyalkanoic acid (PHA), and 3-hydroxybutyrate-co-3-hydroxyhexanoate polymer (PHBH). In particular, from the viewpoint of having excellent biodegradability and flexibility, the biodegradable polymer preferably contains one or more selected from the group consisting of polylactic acid, polyglycolic acid, and poly(ε-caprolactone) (Claim 5).

[0112] In the polymer material according to one embodiment of the present invention, the biodegradable polymer preferably contains a polylactic acid resin, from the viewpoint of having biodegradability while also possessing desirable flexibility. In this specification, a polylactic acid resin refers to a resin in which 40 mol% or more (up to 100 mol%) of lactic acid monomer is present in the total monomers constituting the resin, preferably 45 mol% or more.

[0113] The polylactic acid resin may be polylactic acid, but from the viewpoint of superior biodegradability and flexibility, it may also be a copolymer of a lactic acid monomer and a monomer of a hydroxycarboxylic acid other than lactic acid. Furthermore, the polylactic acid resin may contain a small amount of chain extender residues. The content of the polylactic acid resin in the biodegradable polymer ((mass of polylactic acid resin / total mass of biodegradable polymer) × 100 (mass%)) is preferably 80% by mass or more, more preferably 90% by mass or more, even more preferably 95% by mass or more, particularly preferably 99% by mass or more, and most preferably 100% by mass.

[0114] Lactic acid includes L-lactic acid, D-lactic acid, and DL-lactic acid. Other hydroxycarboxylic acids include difunctional aliphatic hydroxycarboxylic acids such as glycolic acid, 3-hydroxybutyric acid, 4-hydroxybutyric acid, 2-hydroxybutyric acid, 2-hydroxy-3,3-dimethylbutyric acid, 2-hydroxy-3-methylbutyric acid, 2-methyllactic acid, and 2-hydroxycaproic acid, as well as lactones such as caprolactone, butyrolactone, and valerolactone. These may be used individually or in combination of two or more.

[0115] When the polylactic acid resin is a copolymer of lactic acid and a hydroxycarboxylic acid other than lactic acid, the ratio (molar ratio, moles of lactic acid : moles of hydroxycarboxylic acid other than lactic acid) in the polylactic acid resin is preferably 0.1 to 100:1, more preferably 0.5 to 50:1, and even more preferably 0.5 to 20:1.

[0116] In one embodiment, the polylactic acid-based resin contained in the polymer material preferably contains L-lactic acid and ε-caprolactone as the hydroxycarboxylic acid other than lactic acid. By including a polylactic acid-based resin having such a configuration in the polymer material, the flexibility of the polymer material becomes more suitable, and the stent can be expanded more sufficiently in the radial direction.

[0117] When the polylactic acid resin is a copolymer of L-lactic acid and ε-caprolactone, the ratio (molar ratio, number of moles of L-lactic acid: number of moles of ε-caprolactone) of L-lactic acid to ε-caprolactone in the polylactic acid resin is preferably 0.1 to 10:1 (Claim 89), more preferably 0.5 to 5:1, and even more preferably 0.5 to 2:1.

[0118] In a polymer material according to one embodiment, the ratio (mass%) of the mass of the copolymer of L-lactic acid and ε-caprolactone to the total mass of the polymer material may be greater than 25% by mass and 100% by mass or less (Claim 910), 30% by mass or more and 100% by mass or less, 40% by mass or more and 100% by mass or less, 50% by mass or more and 100% by mass or less, greater than 50% by mass and 100% by mass or less, 60% by mass or more and 100% by mass or less, 70% by mass or more and 100% by mass or less, The mass percentage of the copolymer may be 30% to 90% by mass, 40% to 90% by mass, 50% to 90% by mass, over 50% to 90% by mass, 60% to 90% by mass, 70% to 90% by mass, 30% to 80% by mass, 40% to 80% by mass, 50% to 80% by mass, over 50% to 80% by mass, 60% to 80% by mass, or 70% to 80% by mass. By having the mass percentage of the copolymer within the above range, the flexibility and ductility of the polymer material are improved, the occurrence of breakage of the coating is more sufficiently suppressed, and stent expansion defects are also more sufficiently suppressed.

[0119] A polymer material according to one embodiment may contain two or more types of polylactic acid resins. Hereinafter, when two types of polylactic acid resins are included, one of the polylactic acid resins will be referred to as the first polylactic acid resin, and the other as the second polylactic acid resin.

[0120] The first polylactic acid resin and the second polylactic acid resin can be appropriately selected from the polylactic acid resins described above, but it is preferable that the first polylactic acid resin contains L-lactic acid and the second polylactic acid resin contains DL-lactic acid. More preferably, the first polylactic acid resin is a copolymer of L-lactic acid and a hydroxycarboxylic acid other than lactic acid, and the second polylactic acid resin is a copolymer of DL-lactic acid and a hydroxycarboxylic acid other than lactic acid. Even more preferably, the first polylactic acid resin is a copolymer of L-lactic acid and ε-caprolactone, and the second polylactic acid resin is a copolymer of DL-lactic acid and ε-caprolactone.

[0121] In the first polylactic acid resin, the ratio of L-lactic acid to ε-caprolactone in the polylactic acid resin can be the same as the ratio used when the polylactic acid resin is a copolymer of L-lactic acid and ε-caprolactone. Furthermore, the ratio (molar ratio, moles of DL-lactic acid:moles of ε-caprolactone) of DL-lactic acid to ε-caprolactone in the second polylactic acid resin is preferably 1 to 20:1, more preferably 5 to 10:1, and even more preferably 8 to 10:1.

[0122] In the polymer material according to one embodiment, the mass ratio (mass of the first polylactic acid resin:mass of the second polylactic acid resin) of the first polylactic acid resin to the second polylactic acid resin is more preferably 0.5 to 10:1, more preferably 0.5 to 8:1, even more preferably 0.5 to 5:1, particularly preferably 1 to 5:1, and most preferably 2 to 4:1. By having this mass ratio within the above range, the flexibility and ductility of the polymer material are improved, the occurrence of breakage of the coating is more sufficiently suppressed, and stent expansion defects are also more sufficiently suppressed.

[0123] Furthermore, the total content of the first polylactic acid resin and the second polylactic acid resin in the polymer material ((mass of the first polylactic acid resin and the second polylactic acid resin / total mass of the polymer material) × 100 (mass%) is preferably 80% by mass or more, more preferably 90% by mass or more, even more preferably 95% by mass or more, particularly preferably 99% by mass or more, and most preferably 100% by mass.

[0124] (Other ingredients) The coating portion may contain other components in addition to the polymer material described above, as long as the effects and benefits of the present invention are not impaired. Other components are not particularly limited, and examples include, when the medical device is intended for insertion into a body cavity or lumen, drugs (bioactive substances) such as anticancer agents, immunosuppressants, antibiotics, antirheumatic drugs, antithrombotic drugs, HMG-CoA reductase inhibitors, ACE inhibitors, calcium channel blockers, antihyperlipidemic drugs, integrin inhibitors, antiallergic agents, antioxidants, GPIIb / IIIa antagonists, retinoids, flavonoids, carotenoids, lipid-improving agents, DNA synthesis inhibitors, tyrosine kinase inhibitors, antiplatelet agents, vascular smooth muscle proliferation inhibitors, anti-inflammatory drugs, bio-derived materials, interferon, and NO production-promoting substances. The amount of other components added is not particularly limited, and the amounts normally used are applied in the same manner. Ultimately, the amount of other components added is appropriately selected considering the severity of the disease to which it is applied, the patient's weight, etc.

[0125] [Method for manufacturing porous structures] One embodiment of the present invention is a method for manufacturing a porous structure used in an in-vivo implant comprising: an expandable cylindrical stent; and a porous structure disposed to cover the stent and configured to expand in accordance with the expansion of the stent's diameter (porous structure preparation step); and a step of applying a coating material containing a polymer material to an arbitrary portion of the outer surface of the porous structure to form a coating portion on at least a part of the outer surface of the porous structure (coating portion formation step), wherein the Young's modulus of the polymer material is greater than 0 MPa and less than 200 MPa. An in-vivo implant using a porous structure manufactured by this method, which covers a stent, will be able to sufficiently expand the stent in the radial direction while preventing the expansion of the porous structure in the radial direction.

[0126] (I) Porous structure preparation process The porous structure preparation step is a step of preparing a porous structure to be used in an in-vivo implant, comprising an expandable cylindrical stent and a porous structure positioned to cover the stent and configured to expand in accordance with the expansion of the stent's diameter.

[0127] In this process, the porous structure may be a commercially available one or a manufactured one. The method for manufacturing the porous structure is not particularly limited as long as it can produce a porous structure having the above-described configuration. As a manufacturing method, for example, the method described in International Publication No. 2008 / 062414 can be applied in a similar manner or with appropriate modifications.

[0128] (II) Covering part forming process The coating formation step involves applying a coating material containing a polymer material to any portion of the outer surface of the skeletal part of the porous structure, thereby forming a coating on at least a portion of the outer surface of the porous structure. Here, the polymer material can be any of those listed in the (polymer material) section of the above-mentioned <coating>.

[0129] The method for applying (coating) a coating material containing a polymer material to any part of the outer surface of a porous structure is not particularly limited, and conventionally known methods such as coating / printing, immersion (dipping method, dip coating method), spraying method, and spin coating method can be applied. Of these, the spraying method is preferred as the application method because it is easy to form a coating even on fine structures such as the voids in the porous structure and easy to fill the voids in the porous structure with the coating material.

[0130] The conditions for the coating material application method using a nozzle are not particularly limited. For example, the discharge pressure is preferably 1 to 10 kPa, and more preferably 2 to 5 kPa. The discharge time is not particularly limited, but is preferably 0.5 to 10 seconds, and more preferably 1 to 8 seconds.

[0131] Furthermore, it is preferable to rotate the porous structure circumferentially while the coating material containing the polymer material is being sprayed onto the porous structure. The circumferential rotation speed is preferably, for example, 5 to 30 rpm, and more preferably 10 to 20 rpm.

[0132] Coating materials containing polymer materials are preferably applied (coated) in a solution containing the coating material (hereinafter referred to as the coating solution). The solvent for the coating solution containing the coating material is not particularly limited as long as it can sufficiently dissolve or disperse the polymer material. Specifically, examples include ketones such as acetone, methyl ethyl ketone, and cyclohexanone; esters such as ethyl acetate; halides such as chloroform; olefins such as hexane; ethers such as tetrahydrofuran (THF) and butyl ether; nitriles such as acetonitrile, propionnitrile, and benzonitrile; aromatics such as benzene and toluene; amides such as N,N-dimethylformamide (DMF); sulfoxides such as dimethyl sulfoxide; and are not limited to these. These may be used individually or in combination of two or more.

[0133] In particular, from the viewpoint of uniformly dissolving polymer materials, solvents such as ketones like acetone, ethers like tetrahydrofuran, and nitriles like acetonitrile are preferred. Furthermore, from the same viewpoint, a preferred embodiment includes at least one solvent selected from the group consisting of acetone, tetrahydrofuran, and acetonitrile, and a more preferred embodiment includes acetone.

[0134] The coating solution is prepared by mixing polymer material, a solvent, and other components added as needed to create a copolymer solution. The order and method of adding the components are not particularly limited. The components can be added to a mixing container all at once or separately, in stages or continuously. The mixing method is also not particularly limited, and known methods can be used. A preferred method for preparing the coating solution involves adding the copolymer to a good solvent and stirring in the good solvent. The stirring method is not particularly limited as long as it can uniformly mix the copolymer solution.

[0135] The concentration of the polymer material in the coating solution is not particularly limited. From the viewpoint of being able to sufficiently dissolve or disperse the polymer material in the solvent, the concentration of the copolymer in the solution is preferably 0.1 to 1,000 mg / mL, more preferably 1 to 500 mg / mL, and particularly preferably 100 to 300 mg / mL. The amount of coating solution to be applied is not particularly limited, but it may be an amount sufficient to fill all the voids in the area to be coated with the coating solution.

[0136] The temperature (liquid temperature) when mixing the above components is not particularly limited, but it is preferably 0 to 60°C, and more preferably 10 to 30°C.

[0137] Furthermore, by drying the applied coating solution, a coating is formed on at least a portion of the outer surface of the porous structure. The coating solution may be dried at room temperature or by applying heat. When heat is applied, the heating temperature is preferably 50°C to 200°C, and more preferably 80°C to 150°C. The drying time is preferably 30 minutes to 24 hours, more preferably 1 hour to 12 hours, and even more preferably 1 hour to 6 hours. For example, if the heating temperature is 80°C to 150°C, the heating time may be 1 hour to 6 hours.

[0138] [Manufacturing method for implantable devices] An in-vivo implant according to one embodiment of the present invention can be manufactured by attaching (crimping) a porous structure, manufactured by the above-described method for manufacturing porous structures, to an expandable cylindrical stent. That is, a method for manufacturing an in-vivo implant according to one embodiment of the present invention includes an attachment step of attaching a porous structure, manufactured by the above-described method for manufacturing porous structures, to an expandable cylindrical stent. With this manufacturing method, the in-vivo implant manufactured by this method can sufficiently expand the stent in the radial direction while preventing the expansion of the porous structure in the radial direction.

[0139] Here, the stent may be a commercially available product or a manufactured product, as long as it has the configuration described in the embodiment. The method for manufacturing the stent is not particularly limited and can be appropriately selected from general manufacturing methods used depending on the structure and material of the stent. For example, a manufacturing method utilizing etching techniques such as laser etching and chemical etching, and a laser cutting technique can be selected.

[0140] Stents can be made of, for example, non-biodegradable materials. Examples of non-biodegradable materials that can be used for stents include carbon fibers, metallic materials, and polymer materials. Preferably, the non-biodegradable material is a metallic material or a polymer material. From the viewpoint of further reducing inflammation associated with stent implantation, it is particularly preferable that the non-biodegradable material is a metallic material. Here, when the stent is made of a metallic material, the metallic material used is not particularly limited, and metallic materials commonly used in the stent product field can be used. Specifically, examples include stainless steels such as SUS304, SUS316, SUS316L, SUS420J2, and SUS630, tantalum, titanium, nickel-titanium alloys, tantalum-titanium alloys, nickel-aluminum alloys, Inconel, gold, platinum, iridium, tungsten, and cobalt-chromium (Co-Cr) alloys. Among stainless steels, SUS316L is preferred because it has the best corrosion resistance. Among cobalt-based alloys, MP35N and L605 are preferred.

[0141] Furthermore, stents can be constructed from polymer materials, for example. Examples of polymer materials that can be used for stents include those commonly used in the stent product field. Specifically, these include polyolefins such as polyethylene and polypropylene, aromatic polyesters such as polyethylene terephthalate, cellulosic polymers such as cellulose acetate and cellulose nitrate, and fluorine-containing polymers such as polytetrafluoroethylene and tetrafluoroethylene-ethylene copolymers.

[0142] The method for attaching the porous structure to the stent is not particularly limited, and known methods can be used. For example, one method involves placing the porous structure over the stent, pressing it with a pressing body such as silicone rubber, and then irradiating the covering portion with laser light or the like to fix the porous structure to the stent.

[0143] While embodiments of the present invention have been described in detail, these are descriptive and illustrative, and not limiting, and it is clear that the scope of the present invention should be interpreted by the appended claims. [Explanation of Symbols]

[0144] 10 stents 10A Stent Tip 10B Stent base 11 rings 12 Link section 14. First strut section 15. Second strut section 16. Third strut section 17 Curved section 19 Outer surface of the stent 20 Porous structure 20A Tip of the porous structure 20B Base of a porous structure 20C central part of a porous structure 30 Skeletal parts 40 Cavity 50 Covering part 50A Insulated part 50a Covering material 53 Uneven part 53a Convex part 53b Recess 60 Drug handling section 100 Living organisms 200 balloon catheters 220 balloons 300 Stent Delivery System 400A Nozzle 400B Sprayer 500A core metal 500B Jig

Claims

1. A cylindrical stent that can be expanded in diameter, The system comprises a porous structure positioned to cover the stent and configured to expand as the diameter of the stent expands, The aforementioned porous structure is A skeletal structure arranged in a mesh-like pattern, Multiple voids partitioned by the aforementioned skeletal portion, The porous structure comprises a coating portion including a polymer material disposed to cover at least a portion of the outer surface of the porous structure, The covering portion is a biological implant having irregularities formed along the surface shape of the porous structure.

2. The aforementioned covering portion is It has a convex portion that exhibits a convex shape at a position corresponding to the aforementioned skeletal portion, The biological implant according to claim 1, further comprising a recess having a concave shape at a position corresponding to the void, with a smaller covering amount than the convex portion.

3. The covering portion is located at least one of the two ends of the porous structure that are positioned in the axial direction. The biological implant according to claim 1 or claim 2, wherein the amount of coverage of the covering portion gradually decreases from the ends located in the axial direction of the porous structure to the central portion.

4. The biological implant according to claim 1, wherein the porous structure is fixed to the stent via the covering portion.

5. The stent has a drug-carrying portion containing a drug, The biological implant according to claim 4, wherein the covering portion and the porous structure are fixed via the covering portion to an area where the drug-carrying portion is not located.

6. The biological implant according to claim 5, wherein the porous structure is fixed to the curved portion of the stent via the covering portion.

7. The biological implant according to claim 1, wherein the polymer material is a biodegradable polymer.

8. The biological implant according to claim 1, wherein the polymer material has a Young's modulus less than 10 MPa.

9. A porous structure is prepared for use in a biological implant, comprising an expandable cylindrical stent and a porous structure positioned to cover the stent and configured to expand in accordance with the expansion of the stent's diameter. A method for manufacturing a porous structure, comprising dropping a coating material containing a polymer material from a nozzle onto any portion of the outer surface of the porous structure, thereby forming a coating portion having irregularities formed along the surface shape of the porous structure on at least a part of the porous structure.

10. A method for manufacturing a porous structure according to claim 9, wherein a plurality of porous structures are obtained by cutting the porous structure at the position where the covering portion is formed.

Images